San Francisco 49ers defensive lineman Keion White has had surgery after being shot in the ankle. The incident reportedly happened just after 04:00 local time on Monday and the injury is not considered career or life-threatening. The San Francisco Police Department is yet to make an arrest. White attended Sunday's Super Bowl at Levi's Stadium in California as his former team the New England Patriot...
San Francisco 49ers defensive lineman Keion White has had surgery after being shot in the ankle. The incident reportedly happened just after 04:00 local time on Monday and the injury is not considered career or life-threatening. The San Francisco Police Department is yet to make an arrest. White attended Sunday's Super Bowl at Levi's Stadium in California as his former team the New England Patriots lost to the Seattle Seahawks. The 27-year-old was traded to the 49ers in 2025 and, including the play-offs, made 11 appearances last season. The American has featured in 47 games, starting 20, since first being drafted in 2023. He has registered 100 tackles, 7.5 sacks, nine passes defended and two forced fumbles during his time with the 49ers and Patriots. He is the second 49ers player to be shot in the past 18 months after team-mate Ricky Pearsall was injured during an attempted robbery.
Wasserman has not been accused of wrongdoing by any of Epstein's victims, and the appearance of his name in the files does not imply criminal activity of any kind.
Wasserman has not been accused of wrongdoing by any of Epstein's victims, and the appearance of his name in the files does not imply criminal activity of any kind.
Barclays press release ( BCS ): Q4 GAAP EPS of £0.09 beats by £0.02 . Group income of £7.08B (+1.7% Y/Y) beats by £130M . Group RoTE was 8.5% (Q424: 7.5%1 ) with profit before tax of £1.9bn (Q424: £1.7bn). Credit impairment charges were £0.5bn (Q424: £0.7bn) with an LLR of 48bps (Q424: 66bps). Q424 included a £0.2bn day 1 impact from the acquisition of Tesco Bank. Group financial targets1 : 2026 t...
Barclays press release ( BCS ): Q4 GAAP EPS of £0.09 beats by £0.02 . Group income of £7.08B (+1.7% Y/Y) beats by £130M . Group RoTE was 8.5% (Q424: 7.5%1 ) with profit before tax of £1.9bn (Q424: £1.7bn). Credit impairment charges were £0.5bn (Q424: £0.7bn) with an LLR of 48bps (Q424: 66bps). Q424 included a £0.2bn day 1 impact from the acquisition of Tesco Bank. Group financial targets1 : 2026 targets : Returns: Group RoTE of greater than 12%. Capital returns: plan to return at least £10bn of capital to shareholders between 2024 and 2026, through dividends and share buybacks, with a continued preference for buybacks – Progressive increase in total capital returns versus 2025 – Share buybacks announced quarterly – Dividends to be paid semi-annually, including planned £2bn dividend for 2026. Income: Group total income of c.£31bn – Group NII excluding IB and Head Office greater than £13.5bn and Barclays UK NII of £8.1bn - £8.3bn. Costs: Group cost: income ratio of high 50s in percentage terms. Impairment: expect Group LLR of 50-60bps through the cycle. Capital: CET1 ratio target range of 13-14%. 2028 targets : Returns: Group RoTE of greater than 14% • Capital returns2 : plan to return greater than £15bn of capital to shareholders between 2026 and 2028, through dividends and share buybacks. This provides capacity for additional investment and growth, exceeding the level of investment in the current plan • Income: greater than 5% compound annual growth rate ( CAGR ) 2025-2028 • Costs: Group cost: income ratio of low 50s in percentage terms. Cost target includes total gross efficiency savings of c.£2bn in 2026-2028 • Impairment: expect Group LLR of 50-60bps through the cycle • Capital: CET1 ratio target range of 13-14% – IB RWAs of c.50% of Group RWAs. More on Barclays Barclays: Is There Still Value Ahead Following A Strong Share Price Rally? Barclays: ROTE Target Should Be Raised To ~15% Barclays, NatWest to submit rival bids for Evelyn Partners - report Barclays buys ...
AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes drug. Earnings per share, excluding some items, are expected to rise by a low double-digit percentage, the UK drugmaker said Tuesday . That’s in line with what than analysts anticipated. Astra also reported fourth-quarter profit and revenue ...
AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent expiry of a blockbuster diabetes drug. Earnings per share, excluding some items, are expected to rise by a low double-digit percentage, the UK drugmaker said Tuesday . That’s in line with what than analysts anticipated. Astra also reported fourth-quarter profit and revenue that roughly met estimates. Under Chief Executive Officer Pascal Soriot , Astra has become a cancer-drug powerhouse and one of the top two largest companies on the London Stock Exchange . The viability of Soriot’s ambition to reach $80 billion in revenue by the end of the decade will become clearer this year as the drugmaker seeks to almost double sales compared with 2023. Astra has been pushing to boost its pipeline of weight-loss medicines, most recently with a deal worth as much as $18.5 billion with Chinese company CSPC Pharmaceutical Group Ltd . The deal gives Astra access to CSPC’s long-acting peptide technology that could enable monthly dosing, one of the hottest targets as drugmakers compete for the next generation of treatments in a booming market led by Eli Lilly & Co. and Novo Nordisk A/S.
Brookfield Asset Management Ltd. is near a deal to to acquire Dentsu Group Inc. ’s headquarters building in Tokyo for about ¥300 billion ($1.9 billion), according to people familiar with the matter. The New York-based investment management firm is in final talks to buy the property from a special purpose company run by Hulic Co. and others, and expects to close the deal by the end of March, the pe...
Brookfield Asset Management Ltd. is near a deal to to acquire Dentsu Group Inc. ’s headquarters building in Tokyo for about ¥300 billion ($1.9 billion), according to people familiar with the matter. The New York-based investment management firm is in final talks to buy the property from a special purpose company run by Hulic Co. and others, and expects to close the deal by the end of March, the people said. Discussions are ongoing and the parties may decide against proceeding with a deal, the people added. Ad firm Dentsu sold the 48-story skyscraper to the SPC in 2021 for ¥300 billion to improve its balance sheet. It entered an 11-year lease agreement with the SPC that year. If the transaction is completed, it would continue the trend of large real estate deals in Tokyo. Investor demand for commercial properties in the capital has been strong, as indicated by the purchase by KKR & Co. and PAG of a property portfolio including Yebisu Garden Place in 2025 and the deal for Tokyo Garden Terrace Kioicho by Blackstone Inc. — both worth around ¥400 billion or more. A spokesperson for Brookfield wasn’t immediately able to comment. A Hulic spokesperson declined to comment. Brookfield opened a Japan office about 10 years ago and has been expanding its business in the country in recent years. At the end of 2024 it acquired a stake in Meguro Gajoen, a complex that includes a hotel, wedding hall and offices.